Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Other Current Assets

Current assets not reported separately, such as prepaid expenses.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Other Current Assets · Q1 FY2026 · quarter ended Mar 2026

Other current assets falls 54.4% from a year ago

Other current assets stood at $2.08M at the end of Q1 FY2026, down 54.4% from a year earlier and up 37.6% from the prior quarter. Over 3 fiscal years it compounded at +98.9% a year.

Context

  • Other current assets amounted to 1.4% of total assets at the end of Q1 FY2026, down 1.8 pp from a year earlier.
  • Other current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether other current assets keeps falling in the next quarterly balance sheet after a -54.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.08M+37.6% QoQ
Last fiscal yearDec 2025
$1.52M-61.3% YoY
Year agoMar 2025
$4.57M-54.4% since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.4%——
1 year-61.3%——
3-year CAGR+98.9%——
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
1.52M USD
Year-over-year change
-61.3%
4-year CAGR
+67.5%

Other Current Assets vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -54.4% is the 6th highest of 8, against a peer median of -39.7%.
  • Other current assets amounts to 1.4% of total assets for CRBP, versus a peer median of 1.3%.
CRBP Competitors
Other Current Assets for CRBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALECAlector, Inc.Mar 2026$8.57M USD-29.2%—3.6%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$2.08M USD-54.4%+98.9%1.4%
PEPGPepGen Inc.Mar 2026$1.97M USD-39.7%-16.3%1.3%
MOLNMolecular Partners AGMar 2026CHF 1.84M CHF-11.0%—2.1%
RANIRani Therapeutics Holdings, Inc.Mar 2026$1.58M USD+18.4%+46.4%3.0%
CRDFCardiff Oncology, Inc.Mar 2026$1.1M USD-54.7%-32.1%2.2%
FBRXForte Biosciences, Inc.Mar 2026$242K USD-46.1%+82.0%0.4%
ELTXElicio Therapeutics, Inc.Mar 2026$162K USD-79.7%+26.6%0.7%
MISTMilestone Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
IPHAInnate Pharma S.A.Dec 2025-€4.28K EUR——0.0%
Peer median (excluding CRBP) —-39.7%+26.6%1.3%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.01M17M13.72M17.2M28.49M
Short-term Investments72.64M42.19M7.18M131.86M134.78M
Net Receivables00001.5M
Inventory00000
Other Current Assets192.48K192.48K192K3.91M1.52M
Total Current Assets100.2M60.18M23.55M152.98M166.95M
Property, Plant & Equipment (Net)7M5.5M4.04M2.52M1.24M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets523.81K632.77K690K385K0
Total Non-current Assets7.53M6.13M4.73M2.9M1.24M
Total Assets107.73M66.31M28.27M155.88M168.2M
Account Payables1.78M2.17M3.18M4.79M2.22M
Short-term Debt3.86M3.15M16.21M00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities133.71K36.87K39K2.28M2.86M
Total Current Liabilities17.01M12.64M31.89M11.82M20.69M
Long-term Debt15.64M15.98M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities22.21K22.21K44K00
Total Non-current Liabilities21.61M20.68M3.28M1.63M0
Total Liabilities38.62M33.32M35.18M13.45M20.69M
Common Stock12.52K41701K2K
Retained Earnings(349.73M)(392.08M)(436.68M)(476.89M)(555.43M)
Accumulated OCI(62.45K)(126.09K)(1K)35K(53K)
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity69.11M32.99M(6.91M)142.43M147.5M
Total Debt26.59M25.09M20.89M3.24M1.63M
Net Debt1.58M8.09M7.16M(13.96M)(26.86M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.